

LETTER OF INVITATION

**THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT -
STOCK COMPANY**

To: Shareholder:
Shareholder ID:
Citizen ID Card/Business Registration Certificate No:
Address:
Number of shares: share(s)

The Board of Directors (BOD) of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company respectfully invites our shareholders to attend the Annual General Meeting of Shareholders 2026, as follows:

- 1. Time: 8:00 AM, May 5, 2026**
- 2. Venue: Thang Loi Hotel, No. 200 Yen Phu Street, Tay Ho Ward, Hanoi City, Vietnam**
- 3. Meeting agenda:** As per the attached agenda.
- 4. Meeting documents:**

Shareholders are kindly requested to view the meeting documents on the Company's website: <http://dnapharma.com.vn/> under the Shareholder Relations section from April 13, 2026.

5. Attendees:

All shareholders currently holding shares of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company as of the shareholder list closing date of April 6, 2026 are eligible to attend. Shareholders unable to attend the meeting may authorize another person to attend on their behalf in writing using the Company's form.

6. Registration and attendance confirmation period:

Shareholders are requested to confirm their attendance or authorize a representative to attend the Annual General Meeting of Shareholders 2026 (on the next page of this Letter of Invitation) before 16:00 on April 10, 2026, by sending it in person or by mail to the following address:

Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company

Address: No. 16 Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

Tel: 0238 384 1642

When attending the meeting, Shareholders are requested to bring the original Citizen Identity Card ("CIC")/Passport or other legal personal identification documents, Power of Attorney (if



authorized), Letter of Invitation to Meeting, and all documents sent along with the letter of invitation. In case an authorized person of an individual shareholder attending the meeting cannot present the original Letter of Invitation to Meeting, in addition to the original CIC/Passport or other legal personal identification documents and the Power of Attorney, the authorized person must present a certified copy of the CIC/Passport or other legal personal identification documents of the authorizing party.

Sincerely /.

ON BEHALF OF THE BOARD OF
DIRECTORS
CHAIRPERSON



Nguyễn Văn Thang





ATTENDANCE REGISTRATION FORM

The Shareholder (Shareholder Code: _____) hereby confirms attendance or authorization of attendance at the 2026 Annual General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company by marking (X) in one of the boxes below:

1. Attend in person:
2. Authorize a representative to attend:

In the event that the Shareholder authorizes another person to attend the Annual General Meeting of Shareholders, please complete the authorization details in accordance with the Power of Attorney form attached to the Meeting Invitation and submit it directly to the following address:

Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company
Address: No. 16 Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province
Telephone: (+84) 238 384 1642

date month year 2026

SHAREHOLDER

(Sign & Full Name / Seal if applicable for corporate shareholders)

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness



....., date month year 2026

POWER OF ATTORNEY

ATTENDING THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT
- STOCK COMPANY

To: Organizing Committee of Annual General Meeting of Shareholders 2026
Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company

AUTHORIZING PARTY:

Name of shareholder: .. Code:

Citizen ID/Business Licence No. (for organization):.....

DoI (Date of Issue):

PoI (Place of Issue):

Address:

Phone number:

No. of shares owned/represented: shares of Nghe An Pharmaceutical Medical
Material and Equipment Joint - Stock Company

(In word:))

AUTHORIZED PARTY:

Name of individual:..... Code:

Citizen ID:

DoI: PoI:

Address:

Phone number:

No. of shares owned/represented: shares of Nghe An Pharmaceutical Medical
Material and Equipment Joint - Stock Company

(In word:))

CONTENTS OF AUTHORIZATION:

No. of shares authorized:shares

(In word:))

The Authorized Party, on behalf of the Authorizing Party, is hereby empowered to attend the 2026 Annual General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company , to make statements, vote, and participate in elections (if any) on matters within the authority of the Meeting; and to exercise all rights and obligations of the Authorizing Party as a shareholder related to the Meeting, within the scope of the authorized shares. The voting rights shall correspond to the number of shares represented.

This Power of Attorney is valid from the date of signing until the closing of the Meeting. The authorized representative attending the Meeting must not further delegate this authority to a third party.

The Authorizing Party assumes full legal responsibility for this authorization and undertakes not to raise any complaints or claims against Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company .

AUTHORIZING PARTY

(Sign & Full Name / Seal if applicable for corporate shareholders)

AUTHORIZED PARTY

(Sign & Full Name / Seal if applicable for corporate shareholders)



DNA PHARMA

Chất lượng sống khỏe đẹp hơn

CÔNG TY CP

DƯỢC-VẬT TUYÊN

NGHỆ AN

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT - STOCK COMPANY

No. 16 Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

Tel: 0238 384 1642

Enterprise Code: 2900491298

Website: www.dnapharma.com.vn

AGENDA

OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026

Time: 08:00 May 05, 2026

Venue: Thang Loi Hotel, No. 200 Yen Phu Street, Tay Ho Ward, Hanoi City, Vietnam

TIME	CONTENTS
08:00 – 08:30	- Welcoming guests. - Verifying shareholder eligibility, registering shareholders for the meeting, distributing documents.
08:30 – 08:40	- Report on the verification of shareholder eligibility to attend the General Meeting. - Flag ceremony, statement of purpose for holding the General Meeting, opening of the General Meeting. - Introduction of attendees.
08:40 – 08:50	Approval of the Presidium, the Secretariat, and the Vote - Counting Committee. Approval of the General Meeting Agenda and the Rules of Procedure for the General Meeting.
08:50 – 09:00	Report on performance results in 2025 and business plan for 2026.
09:00 – 09:05	The Company's audited financial statements in 2025.
09:05 – 09:15	Report on the Board of Directors' performance results in 2025 and the direction and plan for 2026.
09:15 – 09:25	Report on the activities of the Board of Supervisors in 2025.
09:25 – 09:45	- Submission for approval of the remuneration settlement for members of the Board of Directors and Board of Supervisors in 2025 and the remuneration plan for members of the Board of Directors and Board of Supervisors in 2026; - Submission for the after-tax profit distribution plan in 2025; - Submission for selecting an auditing firm for the 2026 financial statements; - Submission for amendments to the Company's Charter of Organization and Operation; - Submission for dismissal and election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term; - Other matters within the scope of authority (if any).
09:45 – 10:00	- Approval of the regulations for the by-election of the Board of Supervisors members for the remainder of the 2023-2028 term; Introduction of the list of candidates and organization of the election.
10:00 – 10:15	Discussion and voting on the General Meeting agenda.
10:15 – 10:30	Break
10:30 – 10:45	Report on the results of the vote count and election
10:45 – 10:55	Adoption of the General Meeting Minutes and Resolutions
10:55 – 11:00	Closing speech of the General Meeting.

**THE ORGANIZING
COMMITTEE OF THE
GENERAL MEETING**



Nghe An, April 9, 2026

NOTICE

(Re: Nomination and candidacy for election of additional members of Board of Supervisors for the remainder of the 2023 – 2028 term)

To: Shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company

The Board of Directors (the “BOD”) of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (the “Company”) has received the Application for Resignation from one member of the Board of Supervisors for the 2023 – 2028 term. In order to ensure the structure of the Board of Supervisors, the Company respectfully informs you – the shareholders entitled to attend the meeting – of the nomination and candidacy of a qualified person to become the Member of Board of Supervisors for the remainder of the 2023 – 2028 term in accordance with the following conditions, standards and procedures:

I. Number of additional members to be elected to the Board of Supervisors for the remainder of the 2023 – 2028 term: 01 (one) member.

II. Conditions for candidacy and nomination for the election of additional members of the Board of Supervisors for the remainder of the 2023 – 2028 term:

1. Conditions for becoming Member of Board of Supervisors for the 2023 – 2028 term:

- Not being subject to the provisions of Clause 2, Article 17 of this Law;
- Trained in one of the following majors: economics, finance, accounting, auditing, law, business administration or a major suitable to the business activities of the enterprise;
- Not being a family member of a Member of Board of Supervisors, Director or General Director, or other managers;
- Not being a manager of the Company; not being necessarily a shareholder or employee of the Company, unless otherwise stipulated in the Corporate Charter;
- Not working in the Accounting and Finance Department of the Company;
- Not being a member or employee of an independent auditing firm that audited the financial statements of the Company for 3 consecutive years prior to the audit;
- Other standards and conditions as stipulated by the relevant laws and the Corporate Charter.

2. Conditions for candidacy and nomination for the election of additional members of the Board of Supervisors for the remainder of the 2023 – 2028 term:

Ordinary shareholders have the right to pool their voting rights to nominate candidates for the Board of Supervisors:



- Shareholder or group of shareholders holding from 5% to less than 20% of the voting shares may nominate 01 (one) candidate;
- Shareholder or group of shareholders holding from 20% to less than 30% of the voting shares may nominate a maximum of 02 (two) candidates;
- Shareholder or group of shareholders holding from 30% to less than 40% of the voting shares may nominate a maximum of 03 (three) candidates;
- Shareholder or group of shareholders holding from 40% to less than 50% of the voting shares may nominate a maximum of 04 (four) candidates;
- Shareholder or group of shareholders holding from 50% to less than 60% of the voting shares may nominate a maximum of 05 (five) candidates;
- Shareholder or group of shareholders holding from 60% to less than 70% of the voting shares may nominate a maximum of 06 (six) candidates;
- Shareholder or group of shareholders holding from 70% to less than 80% of the voting shares may nominate a maximum of 07 (seven) candidates;
- Shareholder or group of shareholders holding from 80% to less than 90% of the voting shares may nominate a maximum of 08 (eight) candidates;

In cases where the number of candidates nominated or run by a shareholder or group of shareholders is lower than the number of candidates he (she) is / they are entitled to nominate or run in accordance with the decisions of the General Meeting of Shareholders, the remaining number of candidates will be nominated by the Board of Directors and / or the Board of Supervisors and / or other shareholders. The procedures for the incumbent Board of Directors and Board of Supervisors to nominate candidates for the Board of Supervisors is clearly announced and approved by the General Meeting of Shareholders before the nomination process begins as stipulated.

III. Guidance on procedures and documentation for nomination and candidacy for election of additional members of Board of Supervisors for the remainder of the 2023 – 2028 term

The documentation for nomination and candidacy for election of additional members of Board of Supervisors for the remainder of the 2023 – 2028 term from a shareholder or group of shareholders of the Company who satisfy the above conditions include:

- Application for candidacy or nomination to participate in the Board of Supervisors (in the form).
- Resume (in the form).
- Certified copies of diplomas evidencing the professional qualifications of the candidates (if any).

The above documentation shall be prepared in 01 (one) original and sent to the headquarters of the Company no later than 03 (three) days before the opening of the General Meeting at the following address:

*Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company
Address: No. 16, Nguyen Thi Minh Khai, Thanh Vinh Ward, Nghe An Province
Tel: 0238 384 1642*

Best regards.

Recipients:

- *As addressed above;*
- *Archived by the Organization and Administration Department and the Board of Directors.*

FOR AND ON BEHALF OF BOARD OF
DIRECTORS

CHAIRPERSON



Nguyen Van Thang



SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness



**APPLICATION FOR NOMINATION
CANDIDATE FOR BOARD OF SUPERVISORS
OF NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT - STOCK COMPANY
FOR THE REMAINDER OF THE 2023 – 2028 TERM**

**To: GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT - STOCK COMPANY**

I / We, the shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company named below:

Shareholder ID No.	Name of shareholders	Number of shares currently owned in the Company
.....
.....
.....
.....
.....



Under Notice No. 24./2026/TB-HDQT dated 9/4/2026 regarding the nomination and candidacy for the election of additional members of the Board of Supervisors of the Company for the remainder of the 2023 – 2028 term, I / we hereby nominate the following persons to participate in the election of Members of Board of Supervisors of the Company at the 2026 Annual General Meeting of Shareholders:

**LIST OF NOMINEES
FOR MEMBERS OF BOARD OF SUPERVISORS
OF NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT - STOCK COMPANY**

No.	Full name	Citizen ID Card No.	Date of issue	Place of issue	Nominated position:
1.
2.

I / We hereby certify that the aforementioned nominee has not violated any laws or regulations of the Company, and is fully qualified to participate in the Board of Supervisors as stipulated by the law and the Company.

Attachments:

- Resume of candidate.

Sincerely thanks./.

....., date month 2026
Signature of shareholder
(signature and seal of legal representative) ¹

¹ Including all shareholders participating in the nomination

COMMITMENT OF CANDIDATE FOR BOARD OF SUPERVISORS

I am / We are the nominated candidate(s) for the Board of Supervisors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company for the remainder of the 2023 – 2028 term. I / We commit to the truthfulness and accuracy of the personal information provided with this Application for Nomination and commit to performing my / our duties honestly, diligently, and in the best interests of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company, if elected as Member(s) of Board of Supervisors.

....., date month 2026

CANDIDATE
(signature and full name)



SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness



APPLICATION FOR CANDIDACY
CANDIDATE FOR BOARD OF SUPERVISORS
OF NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT - STOCK COMPANY
FOR THE REMAINDER OF THE 2023 – 2028 TERM

To: GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT - STOCK COMPANY

Full name (organization / individual):
Citizen ID Card / Business Registration Certificate No.: Date of issue: Place of issue:
.....
Address:
Educational attainment: Major:
Having been currently holding:..... share(s) (In words:.....)
Corresponding to the total face value of: VND.

I hereby nominate myself to run for election as Member of Board of Supervisors for the remainder of the 2023 – 2028 term of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company at the 2026 Annual General Meeting of Shareholders.

I hereby pledge the truthfulness and accuracy of the personal information provided with this Application for Candidacy and commit to performing my duties honestly, diligently, and in the best interests of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company if elected as Member of Board of Supervisors.

Attachments:

- Resume of candidate and relevant qualifications.

Sincerely thanks./.

Date month 2026

Signature of shareholder (signature and seal of legal representative)



NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT - STOCK COMPANY

No. 16 Nguyen Thi Minh Khai, Vinh City, Nghe An Province
Phone: 0238 384 1642
Business No.: 2900491298 Website: www.dnapharma.com.vn

WORKING AND VOTING REGULATIONS

**AT THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT - STOCK COMPANY**

Article 1: Scope and Subjects of Application

1. These Regulations govern the organization and conduct of the 2026 Annual General Meeting of Shareholders (“GMS”) of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company.
2. These Regulations set out in detail the rights and obligations of shareholders, their proxies, and other attendees at the Meeting, as well as the conditions and procedures for conducting the Meeting.
3. Shareholders, their proxies, and all attendees at the Meeting are responsible for complying with the provisions of these Regulations.

Article 2: General Principles

1. All shareholders attending the General Meeting of Shareholders must be properly and formally dressed, and must present valid identification documents and all relevant documents for verification of shareholder status at the reception desk and to the Shareholder Eligibility Verification Committee.
2. Upon entering the meeting room, shareholders must sit in their designated seats or areas as assigned by the Organizing Committee and comply with the seating arrangements.
3. Smoking is strictly prohibited in the meeting room.
4. Must communicate in a courteous and friendly manner, maintain order, and observe a serious attitude during the Meeting. Private conversations and the use of mobile phones during the Meeting are not permitted. All mobile phones must be switched off or set to silent mode (*if shareholders need to use their phones, they are kindly requested to do so outside the meeting room*).
5. All attendees must comply with the direction of the Chairperson, and facilitate the smooth, efficient, and lawful conduct of the Meeting.

Article 3: Conditions for Conducting the General Meeting of Shareholders

The Annual General Meeting of Shareholders shall be conducted when the number of shareholders or their proxies in attendance represents more than 50% of the total voting shares.

Article 4: Eligibility for Attendance and Regulations on Proxy Authorization

1. Shareholders who are individuals, or proxies of institutional shareholders, whose names appear on the Company’s shareholder list as of the record date for determining

eligibility to attend the 2026 Annual General Meeting of Shareholders, shall be entitled to attend the Meeting.

2. Shareholders entitled to attend the General Meeting of Shareholders may attend in person or authorize a proxy to attend on their behalf. Such proxy may not further delegate their authority to another person to attend the General Meeting of Shareholders. In cases where more than one proxies is appointed, the number of shares and voting rights of each proxy must be clearly specified.
3. The proxy authorization must be made in accordance with the Company's prescribed form and the provisions of civil law. In cases where shareholders do not use the Company's standard proxy form, the proxy document must clearly state the name of the authorized individual, or organization and the number of shares authorized.
The authorized individual or organization attending the General Meeting of Shareholders must present the proxy authorization document upon registration prior to entering the meeting room.
4. Prior to attending the Meeting, shareholders or their proxies must complete the registration procedures for attendance.

Article 5: Rights and Obligations of Shareholders and Their Valid Proxies Attending the General Meeting of Shareholders

1. All shareholders and their proxies attending the Meeting shall have the right to participate, express opinions on matters included in the agenda as approved by the General Meeting of Shareholders, and vote at the Meeting.
2. All shareholders eligible to attend the Meeting shall have the rights and obligations as prescribed by applicable laws, the Corporate Charter, and these Regulations (upon approval by the General Meeting of Shareholders).
3. Each shareholder/proxy must present the original of valid personal identification documents (including one of the following: Citizen ID Card, National ID Card, Passport, or other legally valid personal identification documents), the invitation letter, and the proxy authorization (if acting as a proxy for an individual or organization) to the Shareholder Eligibility Verification Committee for registration and to receive the voting card, ballot papers, voting slips, and meeting materials in accordance with the Company's regulations.
4. Shareholders attending the Meeting who wish to speak must obtain the consent of the Chairperson. Their remarks must be concise, focused on the key matters to be discussed, and relevant to the agenda approved by the General Meeting of Shareholders. Matters already addressed by previous speakers should not be repeated to avoid duplication. Shareholders may also submit their questions in writing to the Secretariat of the Meeting.
5. Shareholders shall have the right to vote on all matters within the authority of the General Meeting of Shareholders in accordance with the Corporate Charter.
6. Shareholders attending the General Meeting of Shareholders shall, after hearing the reports on the matters to be approved, discuss and adopt such matters by voting.
7. Shareholders arriving after the opening of the Meeting, upon completion of the registration procedures, may attend and vote on the remaining matters subject to voting in accordance with the approved agenda. In such cases, the validity of any resolutions already adopted shall not be affected.

Article 6: Chairperson of the Meeting

1. The Chairperson of the Board of Directors shall act as the Chairperson of the General Meeting of Shareholders or may authorize in writing another member of the Board of Directors to act as the Chairperson of the Meeting convened by the Board of Directors. In the absence of the Chairperson or in the event that the Chairperson is temporarily unable to perform his/her duties, the remaining members of the Board of Directors shall elect one among themselves to act as the Chairperson on a majority basis. If no Chairperson can be elected, the Head of the Board of Supervisors shall preside over the General Meeting of Shareholders for the purpose of electing the Chairperson of the Meeting, and the candidate receiving the highest number of votes shall act as the Chairperson of the Meeting.
2. The Chairperson of the Meeting shall nominate members of the Presidium, the Vote Counting Committee, and the Secretariat of the Meeting for approval by the General Meeting of Shareholders.
3. The Chairperson shall preside over the General Meeting of Shareholders, together with other members of the Presidium, and shall manage the Meeting and address any issues arising (if any) during the course of the Meeting.
4. The Chairperson shall have the right to take necessary and reasonable measures to conduct the Meeting in an orderly manner, in accordance with the approved agenda, and in a way that reflects the wishes of the majority of attendees.
5. The Chairperson shall have the right to require all attendees to comply with inspection or other lawful and reasonable security measures; to request competent authorities to maintain order at the Meeting; and to expel any person who fails to comply with the Chairperson's authority, intentionally disrupts order, obstructs the normal progress of the Meeting, or fails to comply with security inspection requirements.
6. The Chairperson of the Meeting shall have the rights and obligations as prescribed by law and by the Company.

Article 7: Rights and Obligations of the Organizing Committee of the Meeting

1. The Organizing Committee of the Meeting shall be established by the Board of Directors of the Company or by the Chairperson of the Board of Directors under authorization from the Board.
2. The Head of the Organizing Committee shall assign members of the Shareholder Eligibility Verification Committee to carry out procedures for verifying the eligibility of attending shareholders, distribute meeting materials, and perform other organizational tasks.

Article 8: Rights and Obligations of the Shareholder Eligibility Verification Committee

1. The Shareholder Eligibility Verification Committee shall consist of one Head and other members selected by the Organizing Committee of the Meeting.
2. The Shareholder Eligibility Verification Committee shall have the authority to establish supporting teams to assist in fulfilling its duties.
3. The Shareholder Eligibility Verification Committee shall be responsible for verifying the eligibility of shareholders or their proxies attending the General Meeting of Shareholders, carrying out registration procedures for shareholders/their proxies attending the Meeting, and distributing voting cards, ballot papers, and voting slips to shareholders/their proxies.



4. The Shareholder Eligibility Verification Committee shall report to the General Meeting of Shareholders on the results of the verification of attending shareholders.

Article 9: Rights and Obligations of the Secretariat of the Meeting

1. The Secretariat of the Meeting shall be nominated by the Chairperson and approved by the General Meeting of Shareholders, and shall be accountable to the Chairperson and the General Meeting of Shareholders for the performance of its duties.
2. Duties of the Secretariat of the Meeting:
 - To record accurately and faithfully all contents and matters approved by, or noted by, the shareholders/their proxies at the Meeting.
 - To prepare the Minutes of the Meeting.
 - To assist the Chairperson in announcing draft documents, conclusions, and notices to be delivered to shareholders upon request.
 - To receive registration forms for speaking from shareholders/their proxies (if any).
 - To perform other duties as assigned by the Chairperson.

Article 10: Rights and Obligations of the Vote Counting Committee

1. The Vote Counting Committee shall be nominated by the Chairperson and approved by the General Meeting of Shareholders, comprising three (03) members.
2. The Vote Counting Committee shall have the authority to establish supporting teams to assist in fulfilling its duties.
3. Duties of the Vote Counting Committee:
 - To provide instructions on the use of voting cards, ballot papers, and voting slips.
 - To provide guidance on the voting and election rules.
 - To determine the number of votes in favor, votes against, abstentions, and invalid votes; and to determine the results of voting and elections.
 - To report to the General Meeting of Shareholders on the results of vote counting and elections.
4. The Vote Counting Committee shall be responsible for the accuracy and integrity of the tasks performed and the vote counting results.

Article 11: Adoption of Resolutions of the General Meeting of Shareholders

1. Voting method:
 - a. Shareholders and their representatives shall exercise their voting rights at the 2026 Annual General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company by using voting cards and ballot papers. Voting cards and ballot papers shall be pre-printed in the form prescribed by the Organizing Committee of the Meeting, bearing the seal of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company, and shall be distributed to shareholders upon attendance at the Meeting. These documents shall include information on the shareholder code and the number of voting shares of the shareholder or proxy attending the Meeting. Shareholders shall use voting cards to vote on matters submitted for direct voting at the Meeting by raising their voting cards. In addition to matters voted on directly by raising voting cards at the Meeting, for reports, proposals, and other matters (if any), shareholders shall cast their votes by selecting one of the voting options (in favor, against, or abstention) on the ballot papers,

signing for confirmation, and depositing them into the ballot box in accordance with the instructions of the Vote Counting Committee.

- b. The Meeting shall vote on each matter included in the agenda. For each matter requiring approval at the General Meeting of Shareholders, the Chairperson shall request voting to be conducted 03 times in the following order:
 - First round : Votes in favor
 - Second round : Votes against
 - Third round : Abstentions
2. *For direct voting by raising voting cards:* each shareholder or proxy (01 person) shall vote only once (in favor, against, or abstention) for each voting request made by the Chairperson on a matter submitted for approval at the General Meeting of Shareholders. In cases where a shareholder does not cast a vote on any matter, the shareholder shall promptly notify the Vote Counting Committee at the time such matter is put to vote for the purpose of consolidating the voting results.
3. *For voting on reports, proposals, and other matters (if any) by selecting options on ballot papers:* Shareholders shall indicate their choice by marking a “v” or “x” in the appropriate box on the ballot paper.
 - Ballot papers shall be considered valid in the following cases:
 - + The ballot paper is issued by the Organizing Committee of the Meeting and bears the seal of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
 - + The ballot paper is not torn;
 - + The voting content is not erased, altered, or amended;
 - + The voting content is valid, meaning the shareholder has clearly selected one of the three options: in favor, against, or abstention;
 - + The ballot paper bears the signature of the shareholder or the shareholder’s proxy.
 - Ballot papers and voting contents shall be considered invalid in any of the following cases:
 - + The ballot paper is not issued by the Organizing Committee of the Meeting or does not bear the seal of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
 - + The ballot paper is torn, erased, or contains altered information;
 - + The ballot paper does not bear the signature of the shareholder or the shareholder’s proxy;
 - + The shareholder does not mark any box, or marks two or more boxes for the same voting matter, or the ballot paper is altered in a way that makes the selected option unclear; such ballot shall be deemed invalid for that voting matter;
 - + The ballot paper is submitted to the Organizing Committee after the close of voting and after the ballot box has been sealed.
4. The voting thresholds and conditions for the adoption of resolutions of the General Meeting of Shareholders at the Meeting shall be implemented in accordance with the Corporate Charter and applicable laws.

Article 12: Speaking at the Meeting

1. Shareholders/their proxies attending the Meeting who wish to speak must obtain the consent of the Chairperson.



2. Shareholders/their proxies shall make concise statements, focusing on the key matters to be discussed, and in line with the approved agenda of the Meeting. The speaking time for each shareholder shall not exceed 3 minutes.
3. The Chairperson shall arrange for shareholders to speak in the order of registration and shall address shareholders' questions.

Article 13: Minutes and Resolutions of the General Meeting of Shareholders

1. The contents of the General Meeting of Shareholders shall be fully recorded by the Secretariat of the Meeting in the Minutes of the Meeting and approved prior to the closing of the Meeting.
2. The Minutes of the Meeting shall serve as the basis for drafting the Resolutions of the General Meeting of Shareholders.
3. The Minutes of the General Meeting of Shareholders, the adopted Resolutions, and all relevant documents shall be kept and archived at the Company's head office.
4. The Chairperson and the Secretary of the Meeting, or other persons signing the Minutes, shall be jointly responsible for the truthfulness and accuracy of the contents of the Minutes.
5. In the event that the Chairperson or the Secretary/Secretariat refuses to sign the Minutes, such Minutes shall remain valid if they are signed by all other members of the Board of Directors attending the Meeting and contain all required contents as prescribed in this Clause. The Minutes shall clearly state the refusal of the Chairperson or the Secretary/Secretariat to sign the Minutes.

Article 14: Effectiveness

These Working and Voting Regulations shall be publicly announced prior to the General Meeting of Shareholders, and shall take effect immediately upon approval by the General Meeting of Shareholders, and shall apply to the 2026 Annual General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company.

**FOR AND ON BEHALF OF THE GENERAL
MEETING OF SHAREHOLDERS
CHAIRPERSON OF THE MEETING**

**REPORT ON THE BOARD OF DIRECTORS' PERFORMANCE RESULTS IN 2025 AND
THE DIRECTION AND PLAN FOR 2026**

**To: Shareholders of Nghe An Pharmaceutical Medical Material and Equipment
Joint - Stock Company,**

The Board of Directors (“BOD”) of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (“the Company”) respectfully reports to the General Meeting of Shareholders (“GMS”) on the Board of Directors’ performance results in 2025 and the direction and plan for 2026 with the following main contents:

PART I: BOARD OF DIRECTORS' ACTIVITIES IN 2025

1. Current members of the Board of Directors:

The Board of Directors for the 2023-2028 term consists of 3 members, including the following individuals:

- Mr. Nguyen Van Thang – Chairperson of the Board of Directors;
- Mr. Lang Van Hieu – Member of the Board of Directors;
- Ms. Phan Thi Thu Hien – Member of the Board of Directors.

2. Board of Directors' performance results in 2025:

2.1 The Company's business performance results in 2025:

- Net revenue from sales and services rendered: 141,509,190,051 VND
- Profit before tax: 4,188,886,197 VND

- The Company has made provisions for the Reward and Welfare Fund and the Investment and Development Fund in accordance with the Resolution of the 2025 Annual General Meeting of Shareholders as follows:

- + Appropriation of reward and welfare fund (10%): 234,591,089 VND;
- + Appropriation of investment and development (25%): 586,477,722 VND.

2.2 Performance results of the Company's Board of Directors:

The Board of Directors (BOD) operates in compliance with the Enterprise Law, the Charter, and the Company's internal regulations. The BOD holds meetings or seeks written opinions from its members in accordance with the regulations to promptly resolve issues and provide close, timely direction for the Executive Board's activities, ensuring that the Company's production and business operations are carried out in a timely manner without interruption.

The BOD has coordinated closely with the Board of Supervisors (BOS), facilitating their effective control and oversight, while actively supporting the Executive Board in management to jointly achieve the Company's shared goals.

By the end of 2025, the BOD has implemented and completed tasks within its authority as follows:

- Preparations for the Company's 2025 Annual General Meeting of Shareholders:
 - + The BOD coordinated with the Executive Board to carry out procedures for convening and organizing the 2025 Annual General Meeting of Shareholders in accordance with the Company's Charter and legal regulations.
 - + At the 2025 Annual General Meeting of Shareholders (AGM) held on May 29, 2025, the General Meeting of Shareholders approved the main contents as follows: Reports from the Director, the Board of Directors (BOD), Board of Supervisors (BOS) on the performance results in 2024 and plan for 2025; Submissions on the remuneration settlement for the BOD and BOS for 2024, the remuneration plan for 2025, profit distribution plan in 2024, selection of an auditing firm for the 2025 financial statements; and approval of the plan to offer additional shares to existing shareholders to increase the charter capital to 150 billion VND.
- Pursuant to the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025, the Board of Directors has implemented the public offering of additional shares to existing shareholders to increase the charter capital as follows:
 - (i) Approving the implementation of the plan for a public offering of shares to existing shareholders to increase the charter capital;
 - (ii) Approving the registration dossier for public offering of shares to existing shareholders to increase the charter capital;
 - (iii) Approving the selection of Asean Securities Joint Stock Company as the underwriter and the signing of the underwriting agreement, and the commitment to underwrite the share offering to existing shareholders of the Company with Asean Securities Joint Stock Company.
 - (iv) Approving the detailed plan for using proceeds from the public offering to existing shareholders to increase the charter capital;
 - (v) Approving the timeline for implementation of the offering to existing shareholders;
 - (vi) Approving the results of the share offering to existing shareholders and the plan for distribution of undistributed shares:

=> On March 11, 2026, the Company completed the share offering procedures, with the following results: Number of shares successfully offered: 9,000,000 shares, representing 100% of the total shares on offer; Total proceeds from the offering: 90 billion VND; Charter capital after the completion of the offering: 150 billion VND. The Board of Directors (BOD) has approved the offering results, assigning the Executive Board to carry out necessary procedures to amend the Business Registration Certificate and report the offering results to the State Securities Commission (SSC) as specified.

=> On March 27, 2026, the Company was granted the Business Registration Certificate recording the new charter capital, completing the capital increase in accordance with the resolution approved by the General Meeting of Shareholders.
- The Board of Directors (BOD) has implemented the resolutions passed by the 2025 Annual General Meeting of Shareholders (AGM), including: selecting the auditing firm for the 2025 financial statements; appropriating the Company's reward, welfare, and investment and development funds; etc.
- The Company's personnel work:
 - + Consolidate the key personnel of the Executive Board; appoint qualified and experienced managers to steer the Company's business operations;
 - + Set up the Raw Material Development Department and strengthen its staff.

+ Approve the decentralization of human resources and financial authority to the Deputy Director;

- Issuance of internal governance regulations/rules for the Company:

+ Approve and issue regulations, rules, organizational structure, and functional duties of departments in compliance with the Company Charter, legal regulations, and practical operational needs, ensuring that the internal regulations are applied consistently and effectively.

+ Adjust the decentralization of human resources management and financial approval authority of the Company.

- Implementation of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park, Vinh City, Nghe An Province:

+ Pursuant to the 2018 Annual General Meeting (AGM) Resolution, the General Meeting of Shareholders approved the policy to implement the construction investment project of a GMP-standard traditional medicine manufacturing plant at Bac Vinh Industrial Park, Vinh City, Nghe An Province; fully authorized the Board of Directors (BOD) to decide and approve contents related to the Project, direct the implementation of tasks, and complete necessary investment and construction procedures to put the Project into operation in accordance with the law.

+ The Board of Directors has completed the procedures for preparing the investment project, determining the total investment amount, scale, and implementation schedule in accordance with the legal regulations. As of November 2018, the Project was granted the Investment Registration Certificate (IRC), providing the Company with the basis for implementing subsequent procedures.

+ Since 2019, the Company has collaborated with Japanese consultants to research investment in a modern production facility, meeting European, Japanese, and international standards for pharmaceuticals. However, due to the prolonged impact of the Covid-19 pandemic from early 2020 to 2023, the project implementation has been delayed. The Board of Directors and the Executive Board require additional time to study, adjust, and apply advanced, modern technologies during construction and operation to create Vietnamese-branded products.

+ Since 2022, the Company has proceeded with procedures to adjust the Project's objectives, increase its scale and capacity, and amend the implementation schedule to align with the Company's new production and business orientation, allowing additional time to seek partners and contractors for project implementation, as well as to overcome the impacts of the Covid-19 pandemic. On February 24, 2022, the Company received approval from the Management Board of Nghe An South-East Economic Zone for the aforementioned updated and adjustments.

+ Since December 2024, the Company's Board of Directors has initiated procedures to update investor information, adjust the project scale to increase factory capacity in line with the Company's strategic product development orientation, and further adjust the basic construction schedule to bring the project into operation in 2026. As of December 31, 2024, the Company has received approval from the Management Board of Nghe An South-East Economic Zone for the aforementioned updates and adjustments.

+ After working with contractors to prepare cost estimates, finalize construction design drawings, and complete necessary procedures to obtain approval from authorized state agencies, the Board of Directors approved the Master Project Schedule, the procurement and contracting plan, and the construction execution plan for the Plant.

+ During the implementation process, the Executive Board and the Board of Directors (BOD), based on expert advice, will continue to evaluate and review investment items to ensure project efficiency. The BOD will coordinate and direct the Executive Board to expedite progress to bring the Plant into operation soon.



- Other matters within the authority of the Board of Directors.

In 2025, the Company strictly complies with regulations regarding information disclosure, corporate governance reports, and annual reports, ensuring that all operational information is disclosed transparently, thus protecting the rights and interests of the Company and its shareholders.

2.3 Results of monitoring the performance of the Company's Executive Board.:

The Board of Directors (BOD) strictly performs its function of directing and supervising the Board of Management, promptly resolving issues within its authority; and creates favorable conditions for the Board of Management to manage the Company's business operations.

During the task implementation, the Board of Management has always closely followed the Resolutions and targets assigned by the General Meeting of Shareholders (GMS) and the Board of Directors (BOD), and performed its functions and duties within the scope of authority.

In 2025, the Company's operations faced significant challenges due to economic downturns and changes in macro-policies directly impacting our core business. However, the Executive Board made significant efforts, pivoting market and production strategies to gradually regain the competitive edge that constitutes the Company's core strength.

2.4 Board of Directors' Remuneration in 2025:

In compliance with the Resolution of the 2025 Annual General Meeting of Shareholders (AGM), the Company has finalized the total remuneration for the Board of Directors (BOD) for 2023 at 117,000,000 VND (*including personal income tax, 12 months' remuneration, and 01 month's remuneration for the Lunar New Year*). The remuneration structure for the BOD members in 2025 is as follows:

- + Chairperson of the BOD: 5,000,000 VND/month.
- + Member of the BOD: 2,000,000 VND/person/month.

2.5 Reports on transactions with related parties

The list of related persons and related interests has been fully and periodically disclosed by the Company in the Corporate Governance Report in accordance with the legal regulations.

In 2025, there were no transactions between the Company, its subsidiaries, or companies under its control (holding 50% or more of the charter capital) and members of the Board of Directors (BOD) or their related persons; nor were there transactions between the Company and companies in which a BOD member is a founding member or a manager within the last 03 years prior to the transaction.

PART II. DIRECTIONS AND PLANS FOR 2026

1.1. The Board of Directors (BOD) directs and supervises the Executive Board in implementing the 2026 business plan approved by the General Meeting of Shareholders (GMS) based on the following key targets:

- Total revenue: 183.67 billion VND, including:
 - + *Pharmaceutical business revenue: 178.92 billion VND;*
 - + *Revenue from real estate lease agreements: 4.75 billion VND.*
- Profit before tax from core business operations: 10.14 billion VND, including:
 - + *Profit from pharmaceutical manufacturing and business operations: 6.21 billion VND;*
 - + *Profit from real estate lease operations: 3.93 billion VND.*

1.2. The Board of Directors directs and supervises the Executive Board in production, business operations, and investment and development activities as follows:

+ Accelerate the construction progress of the Nghe An Pharmaceutical Manufacturing Plant Project in Bac Vinh Industrial Park, Nghe An Province, to bring it into early operation.

+ Promote the search for and development of new raw materials, aiming to diversify sources for pharmaceutical production. Instruct the Executive Board to research and formulate a plan for cultivating medicinal plants in Nghe An province to create a stable and sustainable supply of raw materials for the Company.

+ Expand business operations and boost market development, particularly in out-of-province markets for company-manufactured products

+ Actively call for and facilitate partners to enter joint ventures for production at the GMP factory.

+ Innovate the product supply mechanism for branches, and by all means, maintain and develop the retail system at the branch level.

1.3. Finance

+ Strengthen debt management and control to avoid capital loss, improve financial regulations, and develop reasonable, cost-effective, and savings-oriented expense norms to enhance the Company's production and business efficiency.

+ Advise on policies for local and inter-provincial sales mechanisms and branch management mechanisms.

1.1. Other works

All departments and units across the Company shall stay united and work together to preserve corporate stability and traditions, foster employee solidarity, and leverage support from authorities and partners; step-by-step overcome challenges, continuously improve infrastructure and working conditions, and enhance welfare to care for the material and spiritual lives of employees.

PART III. CONCLUSION

Above is the Report of the Board of Directors on the evaluation of performance results of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company in 2025, and the orientation of the Board of Directors for 2026. At this General Meeting, the Board of Directors respectfully submits the entire report to the General Meeting of Shareholders for approval.

The Board of Directors (BOD) would like to express our sincere gratitude for the cooperation and support from all shareholders towards the Company in general, and the BOD in particular, throughout 2025. On behalf of the Board of Directors, we wish all shareholders good health, happiness, and success. Wish the General Meeting of Shareholders a great success.

Sincerely,

Recipients:

- Shareholders;
- The Board of Directors, Board of Supervisors;
- Archives: VPTĐ, VT DNA.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRPERSON



NGUYỄN VĂN THANG



No.: 23 /2026/BC-BKS

Nghe An, April 9, 2026

REPORT OF BOARD OF SUPERVISORS

Submitted to the 2026 Annual General Meeting of Shareholders

To: The General Meeting of Shareholders of Nghe An Pharmaceutical Medical
Material and Equipment Joint - Stock Company

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
- Based on the powers and responsibilities of the Board of Supervisors as stipulated in the Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
- Based on the operational situation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company, the Reports of the Board of Directors and the Executive Board, and the operational situation of the Board of Supervisors in 2025;
- Pursuant to the 2025 Financial Statements audited by Nhan Tam Viet Auditing Company Limited..

The Board of Supervisors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company would like to hereby report to the General Meeting of Shareholders on the following main points:

I. SUMMARY OF MEETINGS AND ACTIVITIES OF BOARD OF SUPERVISORS IN 2025

1. Regarding the remuneration of the Board of Supervisors 2025:

In 2025, the Annual General Meeting of Shareholders approved the estimated remuneration for the Board of Supervisors. This remuneration will be applied consistently to the members of the Board of Supervisors throughout 2025, specifically:

- Head of Board of Supervisors : 2,000,000 VND/person/month
- Member of Board of Supervisors : 1,500,000 VND/person/month

2. Meetings and activities of the Board of Supervisors in 2025:

In 2025, the Board of Supervisors held meetings to carry out the duties stipulated in the Corporate Charter, including the following key details:

- Monitoring the implementation of the Resolution of the 2025 Annual General Meeting of Shareholders;

- Monitoring the activities of the Board of Directors and the Executive Board;
- Monitoring the compliance with the legal regulations of the State;
- Reviewing the production and business performance of the Company periodically in accordance with the work program of the Board of Supervisors;
- Reviewing and evaluating the reports on implementation of production and business plan, the financial statements, and the management reports of the Company, providing feedback to help the Company promptly address any issues and ensure that the reports and statements are prepared properly, giving a true and fair view of financial position and business operations of the Company.
- Transactions with stakeholders: The Company did not engage in transactions of sale of goods and rendering of services with key managerial members and individuals related to them. As of the end of the fiscal year, the Company has no outstanding debts to key managerial members and individuals related to them.

The inspection and supervision by the members of the Board of Supervisors are carried out continuously and systematically to promptly grasp the operations of the Company, helping the Company to detect and rectify shortcomings in the management, operation and internal control systems.

I. EVALUATION OF PRODUCTION AND BUSINESS OPERATIONS IN 2025

1. Financial position of the Company in 2025

Unit: billion Vietnamese dong

Items	December 31, 2025	December 31, 2024	Difference	Increase / Decrease rate
	(1)	(2)		
A. Total assets	124.89	125.12	-0.22	-0.2%
1. Current assets	67.41	73.90	-6.49	-9%
2. Non-current assets	57.48	51.21	6.27	12%
B. Total equity	124.89	125.12	-0.22	-0.2%
3. Liabilities	33.50	36.72	-3.21	-9%
4. Owner's equity	91.39	88.40	2.99	3%

The total assets of the Company as of December 31, 2025 were 124.89 billion VND, a decrease of 0.22 billion VND compared to the beginning of the year. As of December 31, 2025, the balance of current assets was 67.41 billion VND, and that of non-current assets was 57.48 billion VND.

The total equity of the Company as of December 31, 2025 was 124.89 billion VND, a decrease of 0.22 billion VND compared to the beginning of the year. As of December 31, 2025, the balance of liabilities was 33.5 billion VND, and that of owner's equity was 91.39 billion VND.

As of December 31, 2025, the balance of overdue debts was 14.39 billion VND, of which 1.55 billion VND was considered uncollectible debt. Provisions have been made for all uncollectible liabilities.

The financial indicators of the Company remained weak, with a quick ratio of below 0.5, and very low profit levels and returns on net revenue, assets and owner's equity, mainly due to outdated machinery and the resulting difficulty of its products in competing in the market.

2. Evaluation of business results of the Company in 2025

Unit: billion Vietnamese dong

No.	Items	Performed in 2025	Performed in 2024	Difference	Growth rate
		(1)	(2)	(3) = (1) - (2)	(4) = (3) / (2)
1	Net revenue from main production and business operations	141.51	172.13	-30.63	-18%
2	Profit before tax	4.19	3.22	0.97	30%
3	Profit after tax	3.22	2.35	0.88	37%

In 2025, the revenue decreased by 30.63 billion VND, equivalent to an 18% decrease compared to 2024, mainly due to a decrease in revenue from processing and manufacturing. The profit before tax reached 4.19 billion VND, an increase of 0.97 billion VND, equivalent to a 30% increase compared to 2024.

3. Assessment of the financial statements of the Company and the accounting books

The 2025 Financial Statements have been audited by Nhan Tam Viet Auditing Company Limited with a fully unqualified audit opinion.

III. COMPLIANCE WITH THE REGULATIONS OF THE CORPORATE CHARTER, THE RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS, AND THE LAWS OF THE STATE

In 2025, the Board of Supervisors did not find any unusual signs in the business operations of the Company. All of the activities of the Company complied with the Law on Enterprises, the Corporate Charter and other legal regulations. The Company strictly adhered to the Resolutions of the Board of Directors and the General Meeting of Shareholders.

IV. RESULTS OF MONITORING BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND OTHER BUSINESS MANAGERS

The resolutions of the Board of Directors have been issued in accordance with the authority of the Board of Directors, and the content of these resolutions complies with the Resolutions of the General Meeting of Shareholders, the Law on Enterprises, the Corporate Charter, and other legal regulations.

The Board of Directors held regular and extraordinary meetings chaired by the Chairperson of Board of Directors, regularly inviting the Board of Supervisors to participate in the meetings to implement the resolutions of the General Meeting of Shareholders; discussing and deciding on important issues, and resolving difficulties in production and business operations.



The Board of Supervisors acknowledges that the Board of Directors and the Board of Management have fully fulfilled their management responsibilities in compliance with the Law on Enterprises, the Corporate Charter, the resolutions of the Shareholders' General Meeting, and other legal regulations.

V. ASSESSMENT OF COORDINATION BETWEEN BOARD OF SUPERVISORS, BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND SHAREHOLDERS

In 2025, the Board of Supervisors received close cooperation from the shareholders, the Board of Directors, the Board of Management, and the managers. The Board of Supervisors received all necessary information, reports, and documents for inspection and supervision, and also received personnel assigned to work with it upon the request.

VI. RECOMMENDATIONS

- The Company should make greater efforts in research and development of new products, maximize production capacity at the factory, and expand and develop its products into markets outside the province to develop its brand and bring benefits to the shareholders.
- Develop sales policies and management mechanisms to enhance competitiveness in the retail market and in bidding for contracts with treatment facilities both within and outside the province.
- Strengthen **debt management and inventory control** to avoid capital loss risks, boost sales; and **recover outstanding debts to ensure capital turnover**. Credit limits should be established for each group / category of customers.
- The Company should consider cost reduction options, especially selling expenses, to increase business profitability.
- The Board of Directors and the Executive Board should continue reorganizing the management, production, and personnel structures of departments and branches towards a streamlined and efficient model.
- The Company should implement the pharmaceutical manufacturing plant project in accordance with the project schedule.
- Continue to revise and supplement procedures and regulations on the management and operation of production and business activities, strengthen inspection and supervision of the internal control system to promptly prevent potential risks in accordance with the recommendations and guidance of the Board of Supervisors during its periodic control reviews conducted in 2025 at the Company.

The Board of Supervisors would like to thank the esteemed Shareholders, the Board of Directors, the Board of Management and the Departments / Divisions for creating favorable conditions for the Board of Supervisors to fulfill its duties under the law and the tasks assigned by the General Meeting of Shareholders.

VII. INSPECTION AND MONITORING PLAN OF BOARD OF SUPERVISORS FOR 2026

- Monitoring the compliance with the legal regulations and the Corporate Charter; the implementation of the Resolutions of the General Meeting of Shareholders; and the implementation of the Resolutions, Decisions and Directives of the Board of Directors.

- Conducting inspections and monitoring of the management and operation of the Board of Directors and the Board of Management in accordance with the provisions of the Corporate Charter.
- Monitoring and evaluating the implementation of the business plan, the investment projects, and the and asset utilization in 2026.
- Reviewing the quarterly and annual financial statements of the Company. Analyzing and evaluating the financial position and capital management and utilization of the Company.
- Inspecting and evaluating the effectiveness and efficiency of the internal control, internal audit, risk management and early warning systems of the Company; Monitoring and inspecting the implementation of cost-saving measures.
- Coordinating closely with the Board of Directors, the Board of Management, the departments / divisions, and the affiliated units to implement, inspect and monitor the production and business activities of the Company more effectively.

We wish our esteemed Shareholders good health, happiness and success. We wish the General Meeting great success.

Best regards./.

Recipients:

- *General Meeting of Shareholders;*
- *Board of Directors;*
- *Board of Management;*
- *Board of Supervisors.*

**FOR AND ON BEHALF OF BOARD OF
SUPERVISORS**
By authorization of the Head of Board of
Supervisors



DAO MANH HUNG

No: 125/2026/BC-DNA

Nghe An, date 09 month 04 2026

**REPORT OF DIRECTOR OF COMPANY ON PRODUCTION AND BUSINESS
RESULTS IN 2025 AND PRODUCTION AND BUSINESS PLAN FOR 2026**

**To: The General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material
and Equipment Joint - Stock Company**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and its relevant guiding documents;
- Pursuant to Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (the ‘Company’);
- Based on the actual situation of the Company.

At this General Meeting, on behalf of the Executive Board of the Company, I would like to report on the operational results in 2025 and present to the General Meeting the targets and duties for 2026.

Part I: Report on Business Results in 2025

1. Business results in 2025

With the attention of the Board of Directors of the Company, and the determination of all officials and employees, the Company achieved the following results in 2025:

No.	Items under Resolution	Performance results in 2025 (billion VND)	Compared to the plan for 2025 (%)	Compared to 2024 (%)
1	Net revenue	141.509	67.15%	82.21%
2	Accounting profit before tax	4.188	49.90%	130.08%
5	Payments into State Budget	4.884		
6	Benefits for employees: Social Insurance, Health Insurance, Unemployment Insurance	Full		

2. Evaluation of production and business results in 2025

- Business: The net revenue of the Company in 2025 was projected to reach 141.509 billion VND, achieving 67.15% of the plan and 82.21% of the target for 2024. Reasons for the decrease in net revenue include:
 - The impact of the global economic recession, which has caused difficulties for business operations in general and the pharmaceutical industry in particular.



- Strong fluctuations, scarcity, and disruptions in the supply of raw materials, leading to unmet production targets.
 - Stricter legal regulations related to the pharmaceutical industry
- Profit: The accounting profit before tax in 2025 was 4.188 billion VND, reaching 49.90% of the plan and 130.08% compared to 2024. The increase in the accounting profit before tax is due to: The Company reduced selling expenses and general and administrative expenses in 2025. The selling expenses in 2025 were 17.2 billion VND, a 16% decrease compared to 20.5 billion VND in 2024. The general and administrative expenses were 15.69 billion VND, a 10% decrease compared to 17.4 billion VND in 2024.
 - The Company has established a Raw Material Area Development Department and restructured its personnel to align with the development direction of the Company.
 - The project for construction of office building and plant in Bac Vinh Industrial Park: Having been currently being implemented in accordance with the plan.
 - Implementing the plan for publicly offering shares to existing shareholders to increase charter capital to 150 billion VND.
 - + In accordance with the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025 and the Resolutions of the Board of Directors regarding the implementation of the plan for publicly offering shares to existing shareholders to increase charter capital, the Executive Board of the Company, in coordination with the consulting unit – ASEAN Securities Corporation, has submitted documents and explanations to the State Securities Commission (the “SSC”) to register for the additional public offering of shares.
 - + On December 26, 2025, the State Securities Commission issued Certificate of Registration for Additional Public Offering of Shares No. 533/GCN-UBCK to the Company.
 - + The Company has implemented the following: Announcing the public offering of shares; finalizing the list of shareholders entitled to purchase shares; implementing the detailed procedures and guidance to the shareholders having not yet deposited their shares to register for purchase; transferring the share purchase right; and carrying out other procedures to increase the charter capital of the Company as prescribed.
 - + On March 11, 2026, the Company completed the share offering procedures. The offering results were as follows: Number of shares successfully offered: 9,000,000 shares, accounting for 100% of the total shares offered; Total proceeds from the offering: 90 billion VND; Charter capital after completion of the offering: 150 billion VND The Board of Directors approved the offering results and assigned the Executive Board of the Company to carry out the necessary procedures to amend the Business Registration Certificate and to report the offering results to the State Securities Commission as prescribed.
 - + On March 27, 2026, the Company was granted a Business Registration Certificate by the Department of Finance of Nghe An Province, recording the new charter capital, completing the capital increase as approved by the General Meeting of Shareholders

Part II: Business Plan Targets and Directions for 2026

1. Production and business plan targets for 2026

- Total revenue: 183.67 billion VND. In which:
 - + Revenue from Pharmaceutical and Medical Equipment business: 178.92 billion VND
 - + Revenue from Real Estate leasing: 4.75 billion VND.
- Profit before tax from main business activities: 10.14 billion VND. In which:

- + Profit from pharmaceutical production and business operations: 6.21 billion VND
- + Profit from real estate leasing operations; 3.93 billion VND.

2. Operational directions for 2026:

- Continue to boost revenue from sale across all segments; assess the difficulties in each segment to develop timely, appropriate and effective solutions.
- For the business segment: Focus on bidding activities. Conduct supplementary bidding for some hospitals in the area to open up new bidding packages;
- Evaluate and select suitable products with high revenue to serve the sales agent system of the branches
- Focus on exploiting core products and market orientation.
 - Encourage and facilitate joint ventures for production at the GMP plant of the Company.
 - Assess the market potential of manufactured goods and the price fluctuations to maintain a reasonable inventory of raw materials, ensuring timely production and increasing competitiveness.
 - Find reasonable solutions and mechanisms to promote sale of manufactured goods at the internal branches and in the provincial markets.
 - Maintain and develop the sales system at the branches, with appropriate policies to sustain and grow it.
- For the production segment:
 - Implement the raw material procurement and strengthen the production to achieve the set production plan.
 - Review to repair and improve the infrastructure and documentation system, for the purpose of the re-evaluation of GMP certification of the Plant.
 - Research and develop the plan for medicinal plant cultivation to create a stable and sustainable supply of medicinal materials for the Company.
 - Strengthen the management of money and goods at the internal branches.
 - Continue to improve the financial and accounting management.
 - Develop solutions to enhance the rapid recovery of outstanding debts, focusing on sales in the treatment sector and sales outside the province.
- For the Administration and Personnel Affairs:
 - Survey and evaluate land locations for lease, sign contracts, renew contracts, and ensure reasonable prices as prescribed.
 - Review and promote the implementation of a reasonable salary payment plan for officials and employees to maintain key personnel of the Company.
 - Continue to refine the restructuring of some branches to align with the operating conditions of the enterprise.
- Closely monitor and implement the schedule of the pharmaceutical manufacturing plant construction project in Bac Vinh Industrial Park as directed by the Board of Directors and the Chairperson of Board of Directors.



The foregoing is the report on production and business performance in 2025 and operational plan for 2026 of the Company.

I respectfully submitted this document to the General Meeting of Shareholders for consideration and approval.

In-charge Deputy Director



Fran Cong Vinh

SUBMISSION

(Re: Approval of the remuneration settlement for members of the Board of Directors and Supervisory Board in 2025 and the remuneration plan for members of the Board of Directors and Supervisory Board in 2026)

To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (“the Company”);
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;

The Board of Directors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company respectfully submits to the General Meeting of Shareholders for approval the remuneration settlement for members of the Board of Directors (“BOD”) and Board of Supervisors (“BOS”) in 2025, and the remuneration plan for members of the BOD and BOS in 2026, specifically as follows:

1. The total remuneration for members of the Board of Directors and Board of Supervisors of the Company for 2025 (including personal income tax, 12 months’ remuneration and 1 month’s remuneration for the Lunar New Year) is: **182,000,000 VND**.

1.1 Total Remuneration of the Board of Directors in 2025: **117,000,000 VND**.

1.2 Total Remuneration of the Board of Supervisors in 2025: **65,000,000 VND**.

2. The estimated remuneration for members of the Board of Directors and Board of Supervisors of the Company in 2026 is as follows:

2.1 Board of Directors:

+ Chairperson of the Board of Directors: 5,000,000 VND/month.

+ Member of the Board of Directors: 2,000,000 VND/person/month.

2.2 Supervisory Board:

+ Head of the Board of Supervisors: 2,000,000 VND/month.

+ Member of the Board of Supervisors: 1,500,000 VND/person/month.

Total estimated remuneration for the Board of Directors and Board of Supervisors in 2026: **182,000,000 VND** (including personal income tax, comprising 12 months’ remuneration and 1 month’s remuneration for the Lunar New Year).

Respectfully submit to the General Meeting of Shareholders for consideration and approval. ✓

Recipients:

- *The General Meeting of Shareholders; CBTT;*
- *The Board of Directors and Board of Supervisors;*
- *Archives: Organization and Administration, the Board of Directors.*

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON ✓



NGUYEN VAN THANG

NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK
COMPANY

---o0o---

No.: 20/2026/TTr-HDQT

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

---o0o---

Nghe An, April 9, 2026

SUBMISSION

(Re: After-tax profit distribution plan in 2025)

To: THE GENERAL MEETING OF SHAREHOLDERS

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (“the Company”);
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;
- Based on the Company’s audited financial statements for 2025.

The Board of Directors (“BOD”) of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company respectfully submits to the General Meeting of Shareholders the following profit distribution plan for 2025:



Unit: VND

NO.	ITEMS	AMOUNT
I	Undistributed after-tax profit	11,958,162,700
1	Accumulated undistributed after-tax profits at the end of the previous period	8,733,814,005
2	Undistributed after-tax profit for 2025	3,224,348,695
II	Appropriation of funds for 2026	
3.1	Reward and welfare fund (10% * Profit after tax 2025)	322,434,870
3.2	Investment and development fund (25% * Profit after tax 2025)	806,087,174
3.3	Dividend distribution	0
4	Retained earnings	10,829,640,656

Respectfully submit to the General Meeting of Shareholders for consideration and approval. nr

Recipients:

- As above;
- The Board of Directors, Board of Supervisors;
- Archives: Office, the Board of Directors.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON 

NGUYEN VAN THANG



**NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 26/2026/TTr-BKS

Nghe An, April 9, 2026

SUBMISSION

(Re: Selecting an auditing firm for the financial statements 2026)

**To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (“the Company”);
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;

To ensure objectivity and comprehensiveness in the auditing of the Company’s business operations, and to enhance transparency and protect shareholders’ rights, the Board of Supervisors (“BOS”) hereby submits to the Annual General Meeting of Shareholders for 2026 for approval the selection of an auditing firm for the 2026 Financial Statements, as follows:

- Based on the list of auditing firms eligible to provide audit services approved by the Ministry of Finance, along with criteria for quality, reputation, competitive proposals, and support, the Company selects the auditor for the 2026 financial statements.
- Authorize the Company’s Board of Directors to select an auditing firm to audit the Company’s 2026 financial statements based on the criteria of the list of qualified auditing firms mentioned above.

Respectfully submit to the General Meeting of Shareholders for consideration and approval

Recipients:

- *The General Meeting of Shareholders; CBTT;*
- *The Board of Directors, Board of Supervisors;*
- *Archives: Organization and Administration, the Board of Directors.*

**ON BEHALF OF THE BOARD OF
SUPERVISORS**

DAO MANH HUNG

SUBMISSION

Amendments to the Company's Charter of Organization and Operation

To: THE GENERAL MEETING OF SHAREHOLDERS

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company");
- Pursuant to the Resolution 1678/NQ-UBTVQH15 on the arrangement of commune-level administrative units of Nghe An province ("the Resolution 1678");
- Pursuant to the Decision No. 36/2025/QD-TTg on the Vietnamese economic sector classification system (effective from November 15, 2025) ("the Decision 36");
- Pursuant to the Resolution No. 15/2026/NQ-HDQT dated 16/03/2026 of the Board of Directors on the approval of the plan to organize the Annual General Meeting of Shareholders in 2026.

Effective July 1, 2025, the Company's head office address will change as follows: **No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province.**

On September 29, 2025, the Prime Minister issued the Decision No. 36/2025/QD-TTg on the Vietnamese economic sector classification system, resulting in the removal/change of some business line codes/sectors of the Company.

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the amendment of the Company's Charter of Organization and Operation ("the Charter") regarding the updating of the registered business line codes/sectors according to the Decision 36 and the Company's head office address due to changes in administrative unit arrangement as follows:

- Amend Clause 3, Article 2 regarding the Company's head office address due to changes in administrative unit arrangement according to the Resolution 1678;
- Amend Clause 1, Article 4 of the Company's Charter regarding the Company's registered business lines to conform with the business codes/sectors that have been changed/removed according to the Decision 36 (as per Appendix 01 on the list of business lines attached to this Submission);
- The General Meeting of Shareholders authorizes the Company's legal representative to review, finalize, and sign the amended Appendix and/or the entire Charter of organization and operation according to the content approved by the General Meeting of Shareholders.

Respectfully submit to the General Meeting of Shareholders for consideration and approval.

Recipients:

- As above;
- The Board of Directors, Board of Supervisors;
- Archives: Office, the Board of Directors.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON**



NGUYEN VAN THANG



Appendix 01: List of business lines

(Attached to the Submission No. 22/2026/TT- HDQT dated 09/04/2026)
 (Amended and supplemented according to the Decision No. 36/2025/QĐ-TTg of the Prime Minister on the Vietnamese economic sector classification system)

No.	Business lines	Codes
1.	Manufacture of pharmaceuticals, chemical drugs, and medicinal materials Details: Manufacture of medicines, functional foods, fortified foods, chemical drugs, medicinal materials, raw materials for drug production, and processing of medicinal materials	2100 (Chính)
2.	Wholesale of other machinery, equipment and spare parts Details: Wholesale of medical supplies and equipment	4659
3.	Wholesale of other household goods Details: Wholesale of medicines, pharmaceuticals, medicinal herbs, functional foods, fortified foods; Buying and selling cosmetics, cleaning products for personal use	4649
4.	Hotels and similar accommodation services	5510
5.	Other short-term accommodation services	5520
6.	Other remaining professional, scientific and technological activities not classified elsewhere Details: Consulting services for scientific and technical transfer of technology in the field of medicine and pharmaceuticals; consulting on technology transfer for the production of pharmaceuticals and cosmetics; compounding of medicines according to prescriptions.	7499
7.	Other food manufacturing not elsewhere classified	1079
8.	Wholesale of food Details: Wholesale of functional foods and fortified foods specialized stores, pharmacies, and drugstores	4632
9.	Wholesale of other specialized products not classified elsewhere Details: Trading in raw materials and auxiliary materials for pharmaceuticals, pharmaceutical products, chemicals, and medicinal herbs	4679
10.	Retail of medicines, medical devices, cosmetics, and hygiene products Details: Operating pharmacies and drugstores.	4772
11.	Food retail Details: Retail of functional foods and fortified foods in specialized stores, pharmacies, and drugstores	4722
12.	Other remaining business support service activities not classified elsewhere	8299
13.	Warehousing and storage of goods	5210
14.	Real estate business, land use rights owned, used or leased Details: Leasing of offices, assets on land	6810
15.	Manufacture of cosmetics, perfumes, soaps, detergents,	2023

	polishes and sanitary preparations Details: Manufacture of cosmetics, soaps, detergents, polishes and sanitary preparations	
16.	Distilling, refining, and blending spirits Details: Alcohol production	1101
17.	Production of non-alcoholic beverages and mineral water Details: Production of non-alcoholic beverages	1105
18.	Wholesale of beverages Details: Wholesale of wine, beer, and soft drinks	4633
19.	Restaurants and mobile food services Details: Restaurant business	5610
20.	Cultivation of spice, medicinal, and perennial aromatic plants	0128
For conditional business lines, businesses are only permitted to operate when they meet all the conditions stipulated by law.		

SUBMISSION

(Re: Dismissal and election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term)

**To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (“the Company”);
- Based on the Resolution No. 15/2026/NQ-HDQT dated 16/03/2026 of the Board of Directors on adopting the Plan for organizing the Annual General Meeting of Shareholders in 2026;
- Based on the resignation letter of Ms. Dang Thi Huong Lan.

The Board of Directors (BOD) has received the resignation letter from Ms. Dang Thi Huong Lan as a member of the Board of Supervisors (“BOS”). In accordance with the Enterprise Law and the Company’s Charter, the BOD hereby submits to the General Meeting of Shareholders for approval the following matters:

1. Approval of Ms. Dang Thi Huong Lan’s resignation as a member of the Company’s Board of Supervisors for the 2023-2028 term;
2. Approval of the election of one additional member to the Board of Supervisors for the remainder of the 2023-2028 term, replacing one member proposed for dismissal.

Based on the nomination documents for the Board of Supervisors’ members, respectfully request that the General Meeting proceed with the election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term.

Respectfully submit to the General Meeting of Shareholders for approval. 

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRPERSON 

Recipients:

- As above;
- The Board of Directors, Board of Supervisors;
- Archives: Office, the Board of Directors.



NGUYEN VAN THANG



**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT - STOCK COMPANY**

No. 16 Nguyen Thi Minh Khai, Vinh City, Nghe An Province

Phone: 0238 384 1642

Business No.: 2900491298

Website: www.dnapharma.com.vn

....., date ... month ... year 2026

DRAFT

ELECTION REGULATIONS

**SUPPLEMENTARY ELECTION OF MEMBERS TO THE BOARD OF SUPERVISORS
FOR THE REMAINING TERM OF 2023-2028**

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT -
STOCK COMPANY**

1. Objectives

- Ensure compliance with the laws and practices of Vietnam.
- Ensure the principles of transparency, democracy, and the legitimate rights of all shareholders; all shareholders have the right to vote.
- Ensure the principle of centralization and organizational stability of the General Meeting of Shareholders.
- Ensure the principle of secret ballot in accordance with the law, and ensure the selection of qualified, capable, and suitable individuals to become members of the Board of Supervisors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company for the remaining term of 2023–2028.

2. Regulations on the supplementary election of members to the Board of Supervisors for the remaining term of 2023–2028:

- The supplementary election of members to the Board of Supervisors for the remaining term of 2023–2028 shall be conducted using the cumulative voting method in accordance with Clause 3, Article 148 of the Enterprise Law 2020, or another method as decided by the General Meeting of Shareholders.
- Each shareholder attending the General Meeting shall be issued a ballot, with the total voting rights calculated as the total number of shares owned and/or represented by proxy x (multiplied) by the number of Board of Supervisors members to be elected as decided by the General Meeting of Shareholders.
- The ballot shall clearly list the names of the candidates for the Board of Supervisors. Shareholders may allocate all of their votes to one or several candidates, or distribute a certain number of votes at their discretion; however, the total number of candidates selected shall not exceed the number of Board of Supervisors members to be elected as decided by the General Meeting of Shareholders. The total number of votes cast for all candidates by a shareholder must not exceed the total voting rights allocated to that shareholder.
- After completing the ballot, it must be placed into the ballot box. In case of mistakes or a change of mind before submission, shareholders may contact the Vote-Counting

Committee/Organizing Committee of the General Meeting to return the spoiled ballot and receive a replacement. No crossing out or erasing is allowed on the ballot.

- A valid ballot is one that meets the above conditions, bears the official seal of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company, and the total votes cast for the Board of Supervisors candidates do not exceed the voting rights allocated on the ballot.
- Invalid ballots include:
 - + Ballots not issued by the Vote-Counting Committee/Organizing Committee of the General Meeting, or without the official seal of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company.
 - + Ballots with names of candidates crossed out, erased, or altered in any way.
 - + Ballots indicating more candidates than the number of Board of Supervisors members to be elected as prescribed.
 - + Ballots with names added that are not on the list of candidates approved by the General Meeting of Shareholders.
 - + Ballots where the total votes cast for Board of Supervisors candidates exceed the voting rights allocated on the ballot.
 - + Ballots that are no longer intact.
 - + Ballots not voting for any candidate on the list of nominated Board of Supervisors members.

3. Principles for determining elected members of the Board of Supervisors for the remaining term of 2023–2028

Elected members of the Board of Supervisors for the remaining term of 2023–2028 shall be determined based on the highest number of votes, starting from the candidate with the most votes and continuing until the number of members decided by the General Meeting of Shareholders is filled. If two or more candidates receive the same number of votes for the final position on the Board of Supervisors, a re-election shall be held among the candidates with the tied votes.

4. Announcement of election results

Based on the Vote-Counting Minutes, the results of the election of members to the Board of Supervisors for the remaining term of 2023–2028 shall be announced by the Vote-Counting Committee immediately at the General Meeting.

These results shall be recorded in the resolution of the General Meeting.

5. Effectiveness

These election regulations shall be publicly disclosed prior to the General Meeting of Shareholders and shall be approved and applied at the 2026 Annual General Meeting of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company.

FOR AND ON BEHALF OF THE GENERAL
MEETING OF SHAREHOLDERS
CHAIRPERSON OF THE MEETING

